Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of “Hold” from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been assigned a consensus rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $62.1667.

Several research analysts have commented on the stock. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 7,250 shares of the business’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total transaction of $359,600.00. Following the completion of the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. The trade was a 29.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the sale, the director directly owned 27,277 shares of the company’s stock, valued at $1,445,681. This represents a 24.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 116,406 shares of company stock valued at $5,911,086 over the last ninety days. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Large investors have recently made changes to their positions in the stock. State Street Corp lifted its stake in Supernus Pharmaceuticals by 1.4% in the fourth quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after acquiring an additional 31,668 shares during the period. Geode Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after acquiring an additional 62,875 shares during the period. Loomis Sayles & Co. L P lifted its stake in Supernus Pharmaceuticals by 12.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock worth $72,007,000 after acquiring an additional 162,905 shares during the period. Stephens Investment Management Group LLC lifted its stake in Supernus Pharmaceuticals by 4.5% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after acquiring an additional 61,120 shares during the period. Finally, Woodline Partners LP lifted its stake in Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after acquiring an additional 490,835 shares during the period.

Supernus Pharmaceuticals Stock Up 2.2%

NASDAQ SUPN opened at $48.69 on Friday. The company has a fifty day moving average of $50.18 and a two-hundred day moving average of $49.73. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of -95.47, a PEG ratio of 1.03 and a beta of 0.57. Supernus Pharmaceuticals has a 52 week low of $30.83 and a 52 week high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.